Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area
Sherpa NN, De Giorgi R, Ostinelli EG, Choudhury A, Dolma T, Dorjee S
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 12 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Universal Human Rights and Social Development Association (UHRSDA)
Según 1 financiador declarado.
Publicación
- Publicado
- 2024-11-01 · Eur Neuropsychopharmacol · vol. 90 · págs. 28–35
- Editorial
- Elsevier BV
- Citado
- 18 citas · más que el 95% de estudios similares · 4.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 52 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Diet and metabolism studies · Muscle metabolism and nutrition · Eating Disorders and Behaviors
- Palabras clave
- Double blind, Placebo, Medicine, Pilot trial, Depression (economics), Creatine, Physical therapy, Internal medicine, Randomized controlled trial, Alternative medicine, Pathology
- MeSH
- humans, creatine, treatment outcome, combined modality therapy, administration, oral, feasibility studies, pilot projects, double-blind method, depression, adult, middle aged, female, male, young adult, cognitive behavioral therapy
6 autores
- Nima Norbu Sherpa🇬🇧Glasgow Caledonian University
- Riccardo De Giorgi🇬🇧 · autor de correspondenciaWarneford Hospital
- Edoardo Giuseppe Ostinelli🇬🇧Warneford Hospital
- Amrita ChoudhurySt. Xavier's University Kolkata
- Tenzin Dolma🇮🇳Uttarakhand Government
- Sangila Dorjee🇮🇳Government of Sikkim; Tamil Nadu Government Multi Super Speciality Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Pre-clinical and clinical evidence proposes that creatine monohydrate, an affordable nutraceutical, could be a useful adjunct to conventional antidepressant treatments. In this pilot feasibility and exploratory study, we investigate the 8-week effects of creatine in addition to cognitive-behavioural therapy (CBT) versus placebo plus CBT in depression. For the primary efficacy outcome of change in Patient Health Questionnaire-9 depression score at study endpoint, we used mixed-model repeated measures analysis of covariance. Logistic regressions were employed to assess acceptability (any-cause dropouts), tolerability (dropouts for adverse events), and safety (patients experiencing one or more adverse events). We calculated effect sizes adjusted for age, sex, and baseline depression score. One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression (mean PHQ-9 = 17.6 ± 6.3) were randomised to either creatine+CBT (N = 50) or placebo+CBT (N = 50). At 8 weeks, PHQ-9 scores were lower in both study arms, but significantly more so in participants taking creatine (mean difference= -5.12). Treatment discontinuations due to any cause and to adverse events, and proportion of participants with at least one adverse event were comparable between study arms. This hypothesis-generating trial suggests that creatine could be a useful and safe supplement to CBT for depression. Longer and larger clinical trials are warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.